Related Experiment Video

Updated: Jul 11, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Metoprolol does not effect myocardial fractional flow reserve in patients with intermediate coronary stenoses

Murat Ozdemir1, Guliz Erdem Yazici, Sedat Turkoglu

  • 1Department of Cardiology, Gazi University School of Medicine, Ankara, Turkey.

International Heart Journal
|September 11, 2007
PubMed

Insights

Metoprolol treatment did not affect myocardial fractional flow reserve (FFR) measurements in patients with intermediate coronary artery stenoses. This finding suggests FFR remains a reliable indicator of stenosis severity even after metoprolol administration.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Physiology

Background:

  • Myocardial fractional flow reserve (FFR) is a key diagnostic tool for assessing the hemodynamic significance of coronary artery stenoses.
  • Intermediate coronary stenoses require careful evaluation to determine the need for revascularization.
  • The potential impact of medications, such as metoprolol, on FFR values is not fully understood.

Purpose of the Study:

  • To investigate the effect of intravenous metoprolol on FFR measurements in patients with intermediate-grade coronary stenoses.
  • To determine if metoprolol administration alters the hemodynamic significance of coronary lesions as assessed by FFR.

Main Methods:

  • Eighteen patients with intermediate coronary stenoses (30-70% narrowing) and preserved ejection fraction underwent FFR measurement.
  • FFR was measured using a pressure wire and intracoronary adenosine before and after intravenous metoprolol administration.
  • Metoprolol was administered to achieve at least a 10% decrease in heart rate.

Main Results:

  • Metoprolol significantly reduced heart rate.
  • Aortic and distal coronary pressures showed minimal changes after metoprolol.
  • The FFR values before (0.83 ± 0.07) and after (0.83 ± 0.08) metoprolol administration were nearly identical, indicating no significant difference.

Conclusions:

  • Metoprolol treatment does not significantly influence FFR values in patients with intermediate coronary stenoses and preserved ejection fraction.
  • FFR remains a reliable index for evaluating coronary stenosis severity irrespective of metoprolol use in this patient group.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...